A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma Leukemia December 2020;34(12):3298-3309
Date
12/01/2020
DOI
10.1038/s41375-020-0857-2Scopus ID
2-s2.0-85084684633 (requires institutional sign-in at Scopus site)
35 CitationsAuthor List
Mikhael J, Richter J, Vij R, Cole C, Zonder J, Kaufman JL, Bensinger W, Dimopoulos M, Lendvai N, Hari P, Ocio EM, Gasparetto C, Kumar S, Oprea C, Chiron M, Brillac C, Charpentier E, San-Miguel J, Martin T
Author
Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of Wisconsin